22.12.2014 06:02:56

Radius Health Study Meets Main Goal In Incident Vertebral Fracture Patients

(RTTNews) - Radius Health, Inc. (RDUS) reported positive top-line 18-month fracture results from the company's Phase 3 clinical trial, dubbed ACTIVE, evaluating the investigational drug abaloparatide-SC for potential use in the reduction of fractures in postmenopausal osteoporosis.

On the primary endpoint, abaloparatide-SC achieved a statistically significant 83 percent reduction of incident vertebral fractures as compared to the placebo-treated group. The ACTIVE trial included an open-label teriparatide injection treatment group that showed a 78 percent reduction of incident vertebral fractures as compared to the placebo-treated group.

On the secondary endpoints as compared to placebo, abaloparatide-SC achieved a statistically significant fracture-rate reduction of 43 percent in the adjudicated non-vertebral fracture subset of patients.

It also achieved a statistically significant reduction of 41 percent in the adjudicated clinical fracture group, which includes both vertebral and non-vertebral fractures; and a statistically significant difference in the time to first incident non-vertebral fracture in the adjudicated non-vertebral fracture as well as the clinical fracture subset of patients.

The most frequently reported adverse events were back pain, arthralgia, upper respiratory infection, hypercalciuria and dizziness.

Nachrichten zu Radius Health Incmehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Radius Health Incmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!